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Abstract
Background: Due to the lack of timely access to resources for critical care, strategic use of antiviral drugs is crucial for
mitigating the impact of novel influenza viruses with pandemic potential in remote and isolated communities. We sought to
evaluate the effect of antiviral treatment and prophylaxis of close contacts in a Canadian remote northern community.
Methods: We used an agent-based, discrete-time simulation model for disease spread in a remote community, which was
developed as an in-silico population using population census data. Relative and cumulative age-specific attack rates, and
the total number of infections in simulated model scenarios were obtained.
Results:We found that early initiation of antiviral treatment is more critical for lowering attack rates in a remote setting with
a low population-average age compared to an urban population. Our results show that a significant reduction in the
relative, age-specific attack rates due to increasing treatment coverage does not necessarily translate to a significant
reduction in the overall arrack rate. When treatment coverage varies from low to moderate, targeted prophylaxis has a very
limited impact in reducing attack rates and should be offered at a low level (below 10%) to avoid excessive waste of drugs.
Conclusions: In contrast to previous work, for conservative treatment coverages, our results do not provide any convincing
evidence for the implementation of targeted prophylaxis. The findings suggest that public health strategies in remote
communities should focus on the wider availability (higher coverage) and timely distribution of antiviral drugs for treatment
of clinically ill individuals.
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Introduction
In the event of an emerging disease, of greatest concerns to
public health are the geographic spread, severity, and time course
of the outbreak. Determining the most effective utilization of
available social, preventive, and therapeutic resources to reduce
population vulnerability and mitigate disease outcomes is the main
focus of the public health response. Understanding the effective-
ness of control measures in population settings with distinct
demographic variables and social structures can inform public
health response plans for the allocation and optimal distribution of
health resources prior to and during the spread of an emerging
infection [1,2].
Emerging infectious diseases are, by definition, novel in type,
scope and/or distribution, and therefore pose a particular
challenge for decision-makers. Decisions related to the optimal
use of health resources and the implementation of community-
specific intervention strategies must be made quickly and in the
face of substantial uncertainty. The 2009 influenza A (H1N1)
pandemic (H1N1pdm09) clearly exemplified this challenge [3].
Canada’s northern remote and isolated communities were
disproportionately affected by the disease and its severe outcomes,
often necessitating medevac to urban areas for hospitalization and
intensive care unit (ICU) admission [4,5]. The differential rates of
infection and hospitalization were particularly high in the first
wave of the H1N1 pandemic in Canada [3,6]. During the first
wave, antiviral drugs were the only pharmaceutical intervention
available. However, limited healthcare resources and a significant
delay in the initiation of antiviral treatment post infection appear
to have been barriers to realizing the full potential that antiviral
drugs may have had in mitigating disease burden especially in
northern communities [7]. Epidemiological data from northern
Manitoba, a centrally located Canadian Province, indicate a
significant delay in antiviral treatment of confirmed cases of
H1N1pdm09 infection, with the mean of 3.5 days post symptoms
(Figure S6 of Text S1). Clinically, in order to maximize the
benefits of antiviral drugs, treatment must be initiated early (within
48 hours of symptom onset) [8].
In northern Manitoba, a significant proportion of the popula-
tion self-identifies as having Aboriginal ancestry. Approximately
35% of Canadian, on reserve communities are considered semi-
isolated, isolated or remote [9]. These communities range from
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having road access but the nearest physician services are more
than 90 km away to having no road access or scheduled flights and
minimal telephone and radio service [8]. Factors such as
multigenerational households, challenging environmental charac-
teristics (e.g. crowded housing, and poor indoor air quality due to
tobacco use), differential prevalence of predisposing health
conditions (e.g. diabetes and asthma) and other types of health
disparities in these population settings (limited access to healthcare
resources and high cost of nutritionally rich foods), put these
communities at much higher risk for serious adverse health
outcomes during a pandemic. More timely access to antiviral
treatment may help to reduce the burden on the healthcare system
in the event of an emerging pandemic by decreasing the number
of individuals from Aboriginal communities requiring hospital and
ICU admission [3].
Although not as effective or cost-effective as vaccination,
antiviral use for the treatment of influenza cases is far more
economical than hospitalization or intensive care. Furthermore,
the time frame required for the development, production and
distribution of a virus-specific vaccine using the conventional egg-
based method ranges from 3 to 6 months once the virus has
emerged [10,11]. Antiviral medication will likely be the only
pharmaceutical option for at least 3 months once the pandemic
strain is identified and therefore the availability and strategic use of
drugs is crucial for mitigating disease in remote and isolated
communities, where the risk of severe outcomes appears to be
significantly elevated compared to the urban populations at more
southern latitudes [3,4].
Strategically, the targeted use of antiviral drugs for the
treatment of illness and/or prophylaxis of close contacts may
require different policies for remote communities compared to
urban populations. A ‘‘one size fits all’’ plan may not provide the
most benefit in the case of antiviral use. Previous work has shown
that demographic characteristics (e.g., age and household compo-
sition) can significantly influence the spread of disease, and
therefore the impact of intervention strategies, in the population
[1,12,13]. We sought to investigate the impact of different antiviral
use strategies on the cumulative and relative age-specific attack
rates (i.e., the fraction of population infected) in a synthetic
population representative of a small, remote community in
northern Canada. Our objectives were to: (i) assess the effect of
antiviral treatment (as a single strategy) and the impact of delays in
start of treatment; and (ii) evaluate the combined effect of
treatment and post-exposure prophylaxis on antiviral effectiveness.
For comparative evaluation, we considered the impact of similar
antiviral strategies in a stylized community with the same
population size, but with demographics (age, gender, employment,
and household composition) shifted to resemble an urban area.
For this study, we employed an agent-based, discrete-time
simulation model for the spread of a novel influenza virus in an in-
silico population. This modelling approach allowed us to capture
network patterns, and the stochasticity involved in person-to-
person transmission, particularly during the early stages of the
disease outbreak. A description of the model structure is provided
in the Materials and Methods section with further details in Text S1.
Simulation Design
We developed an in-silico population of individuals in a lattice-
like environment consisting of homes, workplaces, school class-
rooms, and communal spaces that represent a remote community
in northern Canada. The demographic variables (age, gender,
employment, and household composition) were drawn from
Statistics Canada 2006 census data [14,15,16]. For comparison
purposes, we also created an in-silico environment in which the
demographic variables of the remote community (but not the
population size) were modified to resemble the Winnipeg health
region (Figure S3–S5 in Text S1), an urban center in the province
of Manitoba with a large Aboriginal population.
The agent-based simulation model is comprised of several
modules: (i) a spatial module that divides the in-silico population
into a number of workplaces, homes, school classrooms, and
common spaces; (ii) a temporal module for tracking and advancing
the time in simulations; (iii) an agent demographics module that
maintains attributes of each agent (such as age); (iv) an agent
schedule module that determines the location of each agent at any
particular time; (v) a disease transmission module that governs the
spread of the pathogen in the population; and (vi) a disease
progression module that records and updates the change in the
epidemiological status of each individual agent (Figure S1 in
Text S1).
All the simulation results presented here are averaged over 1000
independent realizations, where each realization was seeded
randomly with an initial infectious case. For each independent
realization, agents’ characteristics were drawn and assigned from
distributions provided in demographic data. We set the time
variable in each simulation to advance in increments of one hour.
Each simulation began at the start of the pre-symptomatic
infectious period for the initial infectious case, and ended when
individuals were only susceptible or recovered (i.e., no exposed,
pre-symptomatic, or infectious cases were encountered in the
population at the current simulation time-step).
The model was implemented using a custom C++ based
simulator that can take advantage of desktop and compute cluster
environments. Simulations were carried out on Sharcnet (Shared
Hierarchical Academic Research Computing Network), as part of
the Compute Canada consortium. Following completion of
simulations on Sharcnet, the resulting outputs were downloaded
to the ABM-Lab 64 core SMP machine [17], and analyzed using
Perl and MATLAB. Further details of the model simulator are
provided in the Materials and Methods section.
Results
Table 1 summarizes the scenarios simulated and discussed here
for an estimated reproduction number R0 = 2.2 for the RC
population. To capture the effect of changes in reproduction
number, we also calibrated and simulated the model for R0 = 1.6
and 2.8. (Figures S13–S20 of Text S1).
Treatment and prophylaxis strategies
We first considered antiviral strategies for treatment of identified
infectious cases with the circulating influenza strain. We then
implemented an additional post-exposure prophylaxis strategy in
which close contacts of identified infectious cases were offered
prophylaxis. A newly identified infectious case is defined as an
agent that started receiving treatment, but not as a result of
contact-tracing identification (i.e., seeking treatment or self-
identify themselves). The treatment and prophylaxis coverages
were varied from 0 to 100% (in increments of 2%). Treatment
coverage refers to the fraction of infectious individuals receiving
treatment, and prophylaxis coverage refers to the fraction of close
contacts (of treated cases) that receives prophylaxis. To ensure that
prophylaxis is offered early on during the latent or pre-
symptomatic period, we considered prophylaxis for only close
contacts occurring in the 24 hours prior to the onset of treatment
for an infectious case. We assumed that treatment continued for
the entire infectious period of an infectious case, which was
sampled from a log-normal distribution for every infected
Antiviral Strategies for Novel Influenza Viruses
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individual (see Text S1). Close contacts who developed disease
while receiving prophylaxis continued antiviral therapy with
treatment at the increased dosage for the entire sampled infectious
period.
We allowed re-prophylaxis of individuals who completed a
course of prophylaxis without developing disease, and were
subsequently identified as a close contact of another identified
infectious case. Prophylaxis was offered if the contact was
identified at least 24 hours after the completion of a previous
course of prophylaxis. For antiviral strategies, we considered three
scenarios for the treatment of identified infectious cases, corre-
sponding to an average delay of 1, 2, or 3 days for the initiation of
treatment after the onset of symptoms. Scenarios with longer
delays between symptom onset and the start of treatment are
closer to the average delay observed in H1N1pdm09 epidemio-
logical data reported for northern Manitoba, Canada where many
remote and isolated communities are found (see Text S1). In each
strategy, we implemented scenarios where post-exposure prophy-
laxis was offered in the community for three weeks and five weeks
after the first infectious case was identified for treatment. While a
short-term period of targeted prophylaxis is generally feasible,
long-term prophylaxis poses significant challenges once the
healthcare system has been overwhelmed. For short-term scenar-
ios, no prophylaxis was offered beyond the end of the term (in both
three and five weeks scenarios), but those who started a course of
prophylaxis towards the end of the program completed their
antiviral regimen. Here, we describe the results for an antiviral
strategy involving a three-week prophylaxis use of drugs. The
results for a 5-week prophylaxis use are presented in Figures S7–
S10 of Text S1.
Age-specific attack rates
The simulation outputs were analyzed for four main age groups
in the population: pre-school children (0 to 5 years of age); school-
aged children (6 to 18 years of age); adults (19 to 49 years of age);
and older adults (50+ years of age). We calibrated the model to
ascertain the probability of transmission, from one infectious agent
to one susceptible contact, using the estimated average R0~2:2
for northern Manitoba [18,19]. With antiviral treatment only and
in the absence of prophylaxis, the variations in age-specific,
cumulative attack rates with different treatment coverage are
shown in Figure 1a–c. School-aged children have considerably
higher attack rates in all scenarios regardless of the delay in the
start of treatment following the onset of symptoms (green curves),
and regardless of the treatment coverage. Also, the oldest age
group (50+ years of age) has the lowest attack rates in all scenarios
(blue curves). We observed that increasing the treatment coverage
has a marginal effect on reducing cumulative attack rates for the
children and older adults, and the delay in start of treatment has
virtually no impact on the magnitude of this reduction. However,
increasing the treatment coverage can have a relatively modest
effect on reducing attack rates in other age groups (red and black
curves). Longer delays in the start of treatment would decrease this
effect particularly for high coverages of treatment.
For comparison purposes, we shifted (modified) the demo-
graphic variables of the remote community (RC) to resemble those
of the Winnipeg health region, the largest urban centre in the
province of Manitoba, which has a significant urban Aboriginal
population. When averaging independent realizations in the
absence of treatment, we found R0~1:4 for the model with
shifted demographics (SD). Simulation results of cumulative, age-
specific attack rates for the SD are shown in Figure 1d–f.
Compared to the scenarios for the original RC demographics
presented in Figure 1a–c, we observed several important
differences. Most conspicuous is the results that the lowest attack
rates are associated with the pre-school children (below 2%), while
the attack rates for the group aged 50 years and older remain in
the same range 2%–4%. The attack rates for school-aged children
(green curves) in all scenarios of SD are significantly lower (below
10%) than those of the original RC demographics (above 20%).
Overall, the reduction in age-specific attack rates is comparable in
the corresponding scenarios for treatment delay between SD and
the original RC demographics.
We also analyzed the simulation outputs for the relative attack
rates (the fraction of infected individuals in each age group) for all
the scenarios discussed above. The results of age-specific, relative
attack rates are shown in Figure 2a–f. Interestingly, the highest
attack rates occur in the school-aged children within the ranges
60%–80% and 30%–50% in the RC and SD demographics,
respectively. Attack rates for pre-school children are below school-
aged children, and lie within the ranges 20%–40% and 8%–20%
in the RC and SD demographics, respectively; but remain above
Table 1. Simulation scenarios presented for treatment and prophylaxis strategies, when prophylaxis was implemented for
3 weeks.
Simulation scenarios Simulation outcomes Demographic scenario R0
Delay in start of treatment
1 day 2 days 3 days
Treatment, no prophylaxis Age-specific cumulative AR* RC 2.2 Fig1a Fig1b Fig1c
SD 1.4 Fig1d Fig1e Fig1f
Age-specific relative AR RC 2.2 Fig2a Fig2b Fig2c
SD 1.4 Fig2d Fig2e Fig2f
Treatment and prophylaxis Overall AR RC 2.2 Fig3a Fig3b Fig3c
SD 1.4 Fig4a Fig4b Fig4c
Wasteful use of prophylaxis RC 2.2 Fig3d Fig3e Fig3f
SD 1.4 Fig4d Fig4e Fig4f
Treatment and prophylaxis Effective use of drugs RC 2.2 Fig6a Fig6b Fig6c
SD 1.4 Fig6d Fig6e Fig6f
Simulation outcomes for R0 = 1.6 and 2.8 are reported in Figures S13–S20 of Text S1.
* AR: attack rate.
doi:10.1371/journal.pone.0089651.t001
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those of adults and 50+ age groups in all scenarios. While
equivalent in the original demographics of RC, attack rates of
adults remain slightly above the group aged 50 years and older in
SD scenarios. Overall, increasing treatment coverage decreases
the relative attack rates in each age group, but the delay in the
start of treatment reduces this effect.
Overall, in the model with RC demographics, increasing
antiviral treatment coverage of infectious cases can have a positive
impact on decreasing the attack rates in all age groups. The effect
is most easily observed when comparing relative attack rates rather
than cumulative attack rates. However, if treatment is not
administered within 24 hours after symptom onset, the observed
effect is very minimal. The ordering of cumulative attack rates
differs between the RC and SD demographics. This observation is
a function of the different age structure of the populations with the
RC population having many fewer individuals in the oldest age
category (50+).
Combined effect of treatment and prophylaxis
We ran simulations for both the RC and SD demographics
when the treatment of identified infectious cases is augmented with
prophylaxis of their close contacts (defined as individuals having
direct contact with the case in the 24 hours prior to case
identification). Simulation results of the cumulative attack rates
and ‘‘wasteful use’’ of prophylaxis are presented in Figure 3a–f for
the RC demographics, and Figure 4a–f for SD demographics. In
our model, the ‘‘wasteful use’’ of prophylaxis refers to the use of
antiviral drugs for those who were identified as close contacts of
infectious cases under treatment, but who were previously infected
and not diagnosed. In this case, administering antiviral treatment
to these individuals is considered ‘‘waste’’, because they will not
develop disease as a result of their close contact. This is due to the
fact that in our model, we assumed that the immunity generated
during primary infection prevents re-infection by the same
influenza strain.
For low treatment coverage (below 10%), increasing prophylaxis
coverage of close contacts has little impact on reducing attack rates
(Figure 3a–c). However, the effect of prophylaxis becomes more
pronounced as the treatment coverage increases above 40%. The
greatest waste of prophylaxis corresponds to the range 5%–20%
treatment coverage in the scenario of 1-day delay for start of
treatment. For longer delays, the range of prophylaxis waste
expands to higher treatment coverages (Figure 3d–f). The overall
waste of prophylaxis is significantly higher in the model with the
original RC demographics compared to SD, and could be as much
as 3 times higher in the range 10%–40% treatment coverage,
which is considered a plausible range for public health to
successfully implement an antiviral treatment policy [20,21]. This
relatively low treatment coverage may result from several factors,
including diagnosis uncertainties for influenza cases, treatment
guidelines for use of antiviral drugs, familiarity with antiviral
agents, access to drug stockpiles, or knowledge of the potential
severity and outcomes of infection. Our simulations suggest that,
when the treatment coverage is relatively low (below 40%),
prophylaxis of close contacts should be targeted at a low coverage
(below 10%) to avoid excessive waste.
Attack rates at different community places
We analyzed the simulation results for attack rates in different
locations of the modeled community: households, workplaces,
schools, and other places. From multiple scenarios, we chose to
present the results for a 1-day delay in start of treatment combined
with the scenario of 3 weeks prophylaxis for both RC and SD
demographics. Figure 5 shows boxplots for these simulations,
indicating that in contrast to the SD demographics, attack rates
among households could be significantly higher than those for
Figure 1. The impact of different coverages (0–100%) of antiviral treatment on the age-specific cumulative attack rates under
different assumptions for the mean time between symptoms onset and the start of treatment (1–3 day delay). Panels a–c (RC) show
results from the model representing the remote and isolated Canadian Aboriginal community, and panels d–f (SD) show results from the model
representing a community with an urban-like shifted demographic structure. Green: School-aged children (6–18); red: adults (19–49); blue: older
adults (50+); black: pre-school (0–5).
doi:10.1371/journal.pone.0089651.g001
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workplaces (possibly due to more crowded households in the RC
compared to SD demographics). In all scenarios, the highest attack
rates correspond to schools for both RC and SD demographics.
Prophylaxis can have a modest impact on reducing household
attack rates in the RC demographics, but this effect is relatively
marginal on attack rates associated with other locations.
Figure 2. The impact of different coverages (0–100%) of antiviral treatment on the age-specific relative attack rates under different
assumptions for the mean time between symptoms onset and the start of treatment (1–3 day delay). Panels a–c (RC) show results from
the model representing the remote and isolated Canadian Aboriginal community, and panels d–f (SD) show results from the model representing a
community with an urban-like shifted demographic structure. Green: School-aged children (6–18); red: adults (19–49); blue: older adults (50+); black:
pre-school (0–5).
doi:10.1371/journal.pone.0089651.g002
Figure 3. The projected effect of combining antiviral treatment of infectious cases with prophylaxis of close contacts on population
attack rates (a–c) and wasteful use of drugs (d–f) in the RC demographics when antiviral treatment delays (for infectious cases)
range from 1 day to 3 days post symptom onset.
doi:10.1371/journal.pone.0089651.g003
Antiviral Strategies for Novel Influenza Viruses
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Drug-use
For antiviral strategies combining treatment of infectious cases
with prophylaxis of close contacts, we analyzed the simulation
outputs for the effective use of drugs (defined as the total drug
usage excluding wasteful use of prophylaxis). The number of
effective courses of drugs used is presented as heat-maps in
Figure 6a–f for the RC and SD demographics models. Contour
curves in Figure 6 correspond to the wasteful use of prophylaxis.
Heat-maps illustrate that the effective use of drug depends
critically on the coverages for treatment and prophylaxis. For an
Figure 4. The projected effect of combining antiviral treatment of infectious cases with prophylaxis of their close contacts on
population attack rates (a–c) and wasteful use of drugs (d–f) in the SD demographics when antiviral treatment delays range from
1 day to 3 days post symptom onset.
doi:10.1371/journal.pone.0089651.g004
Figure 5. Box plots for the projected attack rates in households, workplaces, schools, and other places for RC and SD demographics
with 1 day delay in start of treatment and a 3-week prophylaxis strategy. Red circles are outliers for boxplots between the first and third
quartiles.
doi:10.1371/journal.pone.0089651.g005
Antiviral Strategies for Novel Influenza Viruses
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antiviral strategy with a 1-day delay in the start of treatment after
the onset of symptoms, the largest drug use occurs in the high
range of treatment and prophylaxis (Figure 6a). This range is lower
(in the middle) for the same antiviral strategy in the SD population
(Figure 6d). In the SD demographics, high coverages of treatment
and prophylaxis are associated with lower use of drugs compared
to the middle range. For the RC demographics, as delay in the
start of treatment increases to 3 days, a transition in the range for
effective use of drugs moves toward higher coverages of treatment
and prophylaxis. These results suggest that, in the case of limited
drug supply, early treatment with high coverages of treatment and
prophylaxis will provide maximum benefits both in terms of drug
usage and the reduction of attack rates.
Discussion
Our study, for the first time, provides a comparative evaluation
of antiviral strategies for mitigating the effect of a novel influenza
virus in populations with distinct demographic characteristics,
representative of a remote community and an urban community
in Canada. We compared the outcomes of treatment-only and
combined treatment-prophylaxis strategies in terms of cumulative
and relative attack rates, drug usage, and wasteful use of
prophylaxis in four different age groups in the population.
Qualitatively, we observed several similarities and differences
between the observed outcomes. First is the observation that in
crowded settings with low average age (e.g. RC populations), the
highest attack rate is associated with school-aged children. Delay
in treatment interventions following the onset of symptoms has a
large impact on the effectiveness of antiviral drugs in reducing the
Figure 6. The projected effective use of antiviral drugs when combining antiviral treatment of infectious cases (y-axis) with
prophylaxis of close contacts (x-axis) in the remote community model (RC) (a–c) and the shifted demographics model (SD) (d–f).
Antiviral treatment delays range from 1 day to 3 days post symptom onset. Contours describe the amount of antiviral wastage (counted in the
number of courses given) for dispensing drugs as prophylaxis.
doi:10.1371/journal.pone.0089651.g006
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overall and age-specific attack rates (Figure 1). These observations
can be placed in the context of remote communities of primarily
Aboriginal ethnicity. In these communities, multigenerational
households and strong community social ties can lead to frequent
close contacts allowing influenza to spread throughout the
community relatively easily. When comparing the relative attack
rates for each age-group, we observed similar patterns for both
remote and urban-like demographics, with the highest and lowest
attack rates in school-aged children and individuals aged 50 years
and older, respectively. These findings suggest that a significant
reduction in relative attack rates of a specific age group may not
necessarily contribute to a large reduction in the cumulative attack
rates.
When treatment is implemented alongside prophylaxis of close
contacts, we observed similar patterns for the overall attack rate
in both models for original (RC) and shifted (SD) demographics.
Importantly, the wasteful use of drugs for prophylaxis corre-
sponds to levels of antiviral treatment that are generally most
plausible in public health responses (between 10% and 40%)
[20,21]. Our simulations suggest that, in both demographic
scenarios, when treatment coverage varies from low to moderate,
targeted prophylaxis should be offered at only low levels (below
10% in our simulations) to avoid excessive waste of drugs
(Figures S11 and S12 of Text S1). Within an antiviral strategy
for post-exposure prophylaxis, early treatment of infectious cases
is more crucial to the effectiveness and effective use of drugs.
Maintaining a significant public health response that focuses on
following up close contacts of infectious cases for the provision of
antiviral prophylaxis for a time period in excess of 3 weeks
described here (e.g., 5 weeks) has very little impact on overall
attack rates, and results in a considerably more drug wastage (see
Text S1). Furthermore, such an extended period of prophylaxis
contributes to a significant workload to an already overburdened
health system, particularly during the peak incidence of infection.
We observed qualitatively similar behaviours by simulating our
models for different reproduction numbers (see Text S1).
Figure 7. Compartmentalization of the model structure with four main blocks: (a) prior to becoming symptomatically infectious; (b)
develop symptomatic infection without having received prophylaxis; (c) develop symptomatic infection while receiving
prophylaxis; (d) develop symptomatic infection after completing a course of prophylaxis. Subscripts have the following meaning: (P)
the agent is currently undergoing a course of prophylaxis; (X) the agent is (was) receiving prophylaxis during the pre-symptomatic or exposed period;
(U) the agent is unidentified and therefore not treated (when Infectious, following a delay, the agent may seek treatment with some probability); (T)
the agent is under treatment (or received treatment), and is therefore known to have had the disease. Blue arrows indicate disease progression,
which is influenced by the passage of time and some particular disease parameters. In the case of the S-to-E transition, transmission occurs between
co-located susceptible and infectious individuals in either pre-symptomatic or symptomatic stage. Green arrows indicate self-identification following
a delay in seeking treatment by a symptomatically infectious agent. Red arrows are socially mediated transitions resulting from the identification (i.e.,
contact-tracing) of the agent as having been in contact with a new infectious case within the last 24 hours.
doi:10.1371/journal.pone.0089651.g007
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When treatment is maintained at conservative levels, our
findings do not provide any convincing evidence for the
implementation of community-wide prophylaxis of close contacts.
These findings also suggest that the early initiation of antiviral
treatment is more critical for lowering attack rates in a crowded
setting with a low average age (such as a remote community with
demographic characteristics simulated here) compared to an
urban-like population. Furthermore, a longer delay in the start
of treatment significantly diminishes the effect of increasing
treatment coverage in reducing the overall attack rate (Figures 3–
4).
There is an emerging body of evidence suggesting that there is
a strong correlation between the speed with which antiviral
treatment is initiated following the onset of symptoms and the
degree of disease severity in critically ill patients of influenza
[3,4]. The experience of H1N1pdm09 in Canada’s northern
Aboriginal communities provides compelling evidence for severe
disease outcomes, often necessitating hospitalization and ICU
admission [3,4,6]. Analysis of the age-distribution of the
H1N1pdm09 cases in the province of Manitoba, Canada,
indicates significantly higher rates of infection and hospitalization
amongst First Nations compared to non-First Nations popula-
tions. These rates were as much as 12 times (for infection) and 22
times (for hospitalization) higher in First Nations young children,
aged 0–4, compared to the same age group in non-First Nations
populations [6]. Continued improvements to the health infra-
structure in northern communities during the inter-pandemic
period and focused pandemic planning will permit northern
healthcare providers to more effectively manage the surging
demand for healthcare and specifically antivirals during the peak
of pandemic outbreaks [3].
Model limitations
Any model, regardless of the level of detail included in its
structure, is subject to limitations. While several limitations are
related to the lack of specific data and measurements, others arise
from the assumptions. For example, the mitigation effects of
antiviral drug use on disease spread can be modeled as a reduction
of disease transmissibility from the start of treatment but no
reduction in infectious period, or a reduction in infectious period
but no reduction in transmissibility, or a combination thereof. In a
practical sense, the overall effect of treatment should match the
reduction in secondary attack rates observed in household studies
[22,23]. Since reduction in transmissibility over the entire
infectious period can capture the effectiveness of antivirals, we
chose the first method. We also did not consider antiviral use in
the context of other public health interventions; however, a variety
of interventions (such as vaccination if available, quarantine/
isolation, or social distancing including school closure) may take
place simultaneously during the course of an outbreak.
Our model does not explicitly include asymptomatic infection;
however, a distribution of transmission probabilities in infectious
individuals would address the variability in infectiousness seen in
undiagnosed infectious cases, of which the asymptomatic infections
are a subset. Incorporating a separate class for asymptomatic
individuals in the model can be managed computationally, but we
have steered clear of this additional class in the model because very
little is known about asymptomatic cases, and so the challenge of
finding appropriate data would be significant. Yet, we understand
that antiviral wastage may in fact exceed what we have described
here, due to the possibility of asymptomatic infections. We only
consider waste as a result of giving prophylaxis to ‘‘recovered’’
individuals that were never identified as cases and therefore
recovered naturally from their infection and would be immune
against re-infection with the same strain of influenza. We did not
consider antiviral wastage that might occur as a result of the co-
circulation of other pathogens that cause acute respiratory disease
[24]. Furthermore, our model does not take into account the
evolution of drug resistance. In the context of transmissible drug-
resistance, prophylaxis would only enhance the spread of resistant
strains [25,26]. This is facilitated by a reduction of susceptibility to
the sensitive infection and an increase in vulnerability of
susceptible individuals who are receiving prophylaxis to resistant
infection.
Other limitations related to the lack of specific data include
our basic models for the time-use of individuals during their
regularly scheduled activities, and the level of strain-related pre-
existing immunity in the population. The type of community
modeled is considered to be remote and isolated, and therefore
interactions with other communities are not modelled. Finally,
the model outcomes are quantitatively subject to uncertainty in
disease parameters. We performed simulations based on recent
parameter estimates of H1N1pdm09 data and previous estimates
of antiviral effectiveness. However, the combination of treatment
and prophylaxis is not adequately discussed in the literature,
particularly for remote and isolated communities. While quan-
titative results of our simulations may change with variations in
model parameters, or the choice of modelling approach, we
expect our results to remain qualitatively robust despite the
above limitations.
Materials and Methods
We restructured and calibrated a previously validated agent-
based modelling framework for the spread of influenza infection in
a remote and isolated community in northern Canada, referred to
as RC throughout this paper [1]. We included antiviral treatment
of identified infectious cases, and post-exposure prophylaxis of
close contacts as control measures in the absence of pre-existing
immunity or vaccination.
Modelling framework
To capture the movement and interactions of individuals (i.e.,
agents), we developed an in-silico environment as a lattice-scaled
representation of the community. We considered a Markov Chain
compartmental structure for disease spread, and assumed that at
any particular time, each agent belongs to one of the compart-
ments in the model depending on the particular epidemiological
history of that agent. The basic framework includes the
compartments represented in Figure 7, which correspond to
susceptible, exposed, pre-symptomatic, symptomatic, and recov-
ered classes of agents. To include the effect of antiviral treatment,
we further subdivided these compartments by using subscripts.
The transition between model compartments was a function of
time and other model variables. The type of transition is indicated
by the color of the arrows in Figure 7. A description of model
variables and ranges of parameter values are provided in Table S1
and S2 of Text S1.
Population study
We assume that the remote community (RC) has no road access
to any urban center and air travel is the only possible conduit. The
demographic data (i.e. age, gender, household size, and employ-
ment characteristics) for RC were based on Statistics Canada
census data [27–29] that are rounded to the nearest five
individuals. The population size of each age group, and the
distribution of individuals per household for the original RC
demographics are given in Figures S3–S5 of Text S1. For shifting
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the demographic variables to those of an urban centre (the
Winnipeg health region), we modified the age distribution,
household size, and employment characteristics using reported
census data, while keeping the same population size of RC (see
Text S1).
Model parameterization
For each pair of co-located infectious and susceptible individ-
uals, the probability of transmission is independent and given by
Ptransmission~1{ 1{b 1{q1ð Þ 1{q2ð Þð Þt
Where b is the transmission rate; q1is the reduction in
transmissibility (viral shedding) of an infectious individual due to
antiviral treatment and/or prophylaxis; q2 is the protective effect
of prophylaxis offered to a susceptible individual; and t is the
amount of time spent in potentially infectious contacts. We
assumed that infected individuals during pre-symptomatic stage
are (on average) 50% less infectious than during symptomatic
phase (see Table S2 of Text S1).
In the absence of any antiviral interventions, the rate of disease
transmission, b, was iteratively modified through a series of trials
in order to calibrate the model to an initial reproduction number,
R0, within the estimated ranges for H1N1pdm09 in northern
communities [17]. In our calibration, R0 was calculated by
averaging the number of secondary infections generated by the
initial infectious case in each independent simulation. Each trial
used 10,000 randomly initialized simulation runs. Averaged
calibration trials determined the rate b, with an average
R0~2:2 for the original RC demographics. The corresponding
R0 for (urban-like) shifted demographics was found to be 1.4. For
calculation of relative and cumulative attack rates, we averaged
the total number of infections in different age groups and overall
(throughout the entire course of outbreak) for all simulation trials.
This averaging excluded simulations in which no secondary
infections were generated by the initial infectious case.
We included the overall effect of antiviral treatment in the
reduction of disease transmissibility following the initiation of
treatment. We assumed that treatment reduces the infectiousness
by 60% if the infectious person was not receiving prophylaxis at
the time of exposure [30]. Prophylaxis was assumed to reduce
susceptibility to infection by 30% and transmissibility (if infected)
by 60% [29]. Those who developed symptomatic infection while
receiving prophylaxis and continued with treatment were
assumed to have an additional 60% reduction in infectiousness
[29,31], with an overall 84% reduction of infectiousness (given by
1–(0.460.4) = 0.84). We assumed a probability of 0.65 that
individuals receiving prophylaxis will have significantly milder
symptomatic infection (if they developed illness) [30,31], and
therefore will not seek treatment. A course of prophylaxis in the
model simulations lasted for 7 days. Previous work [32]
considered a longer duration of prophylaxis (about 10 days);
however, considering possible compliance issues, we assumed a
shorter prophylaxis period. Individuals that were previously
receiving prophylaxis were not eligible to receive a subsequent
course of prophylaxis if identified as a close contact within
24 hours of completing the previous course. Symptomatically
infectious individuals who are identified as a close contact were
offered antiviral treatment, unless they were symptomatically
infectious for more than 48 hours prior to identification. A
course of treatment for each individual spanned for the entire
duration of infectiousness.
The exposed period was drawn from a uniform distribution with
a minimum of 1 day and a maximum of 2 days [33]. The pre-
symptomatic period for each infected individual was drawn from a
log-normal distribution with the scale parameterm~{0:775 days,
and shape parameter s2~0:16 days, giving an average of 0.5 days
[34]. The duration of symptomatic infection was sampled from a
log-normal distribution (Figure S2 of Text S1), with the scale
parameter m~1 day, and the shape parameter s2~0:4356 days,
which has a mean of 3.38 days [35]. In our model, we used 1000
independent realizations to sample the resulting generation times
in the absence of any interventions. Averaging the time interval
from the start of pre-symptomatic period of the initial infectious
case to the start of pre-symptomatic period of the earliest
secondary case in these realizations resulted in 69.3 hours, giving
a generation time of approximately 2.9 days (95% confidence
interval: 25–131.3 hours), which lies within the estimated range
for H1N1pdm09 [36–38]. Again, without interventions, we
calculated the generation time throughout the outbreak [39,40],
using the same method applied to infectious cases beyond the
initial case. We ran 1000 independent realizations, and averaged
the individual generation times for each epidemic episode to
determine the generation time distribution. We estimated the
mean generation of 71.9 hours (approximately 3 days) with the
95% confidence interval 24–133 hours. These simulations
provided an average doubling time of 34 hours (1.4 days) for the
time interval between the introduction of the first infectious case to
the time of exposure of the earliest secondary case. The delay in
seeking treatment after the onset of symptoms was sampled from a
uniform distribution with a minimum of 0.5 days, and a mean of
1, 2, or 3 days, corresponding to the simulated scenarios.
Supporting Information
Text S1 Supplementary Information. Details of model
structure, parameter values, and further simulation scenarios.
(PDF)
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